Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone M Goldinger

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Cancer Immunology, Immunotherapy : CII|February 27, 2019
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysisBastian Schilling, Alexander Martens, Marnix H Geukes Foppen, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaLisa Zimmer, Susmitha Apuri, Zeynep Eroglu, et al.
British Journal of Cancer|February 14, 2018
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patientsMarkus Hecht, Friedegund Meier, Lisa Zimmer, et al.
Science (New York, N.Y.)|September 12, 2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanomaEliezer M Van Allen, Diana Miao, Bastian Schilling, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2018
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective studySara Valpione, Matteo S Carlino, Johanna Mangana, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2018
Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]Sara Valpione, Matteo S Carlino, Johanna Mangana, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infectionMartin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2016
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyLisa Zimmer, Simone M Goldinger, Lars Hofmann, et al.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2016
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyLars Hofmann, Andrea Forschner, Carmen Loquai, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2015
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsDouglas B Johnson, Alexander M Menzies, Lisa Zimmer, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Cancer Immunology, Immunotherapy : CII|February 27, 2019
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysisBastian Schilling, Alexander Martens, Marnix H Geukes Foppen, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaLisa Zimmer, Susmitha Apuri, Zeynep Eroglu, et al.
British Journal of Cancer|February 14, 2018
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patientsMarkus Hecht, Friedegund Meier, Lisa Zimmer, et al.
Science (New York, N.Y.)|September 12, 2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanomaEliezer M Van Allen, Diana Miao, Bastian Schilling, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2018
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective studySara Valpione, Matteo S Carlino, Johanna Mangana, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2018
Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]Sara Valpione, Matteo S Carlino, Johanna Mangana, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infectionMartin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2016
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyLisa Zimmer, Simone M Goldinger, Lars Hofmann, et al.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2016
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyLars Hofmann, Andrea Forschner, Carmen Loquai, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2015
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsDouglas B Johnson, Alexander M Menzies, Lisa Zimmer, et al.
Pageof 7